



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/645, 31/405, 31/195 // (A61K 31/645, 31:405, 31:195)		A1	(11) International Publication Number: WO 98/08520
			(43) International Publication Date: 5 March 1998 (05.03.98)
(21) International Application Number: PCT/GB97/02295 (22) International Filing Date: 27 August 1997 (27.08.97) (30) Priority Data: 9617990.8 29 August 1996 (29.08.96) GB (71) Applicant (for all designated States except US): SCOTIA HOLDINGS PLC [GB/GB]; Weyvem House, Weyvem Park, Portsmouth Road, Peasmarsh, Guildford, Surrey GU3 1NA (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): HORROBIN, David, Frederick [GB/GB]; Scotia Holdings plc, Scotia House, Castle Business Park, Stirling FK9 4TZ (GB). CARI, Loder [GB/GB]; 7 Swinton Street, Kings Cross, London WC1 (GB). GRAHAM, Cooper [GB/GB]; Scotia Holdings plc, Scotia House, Castle Business Park, Stirling FK9 4TZ (GB). (74) Agent: FARWELL, William, Robert; Phillips & Leigh, 7 Staple Inn, Holborn, London WC1V 7QF (GB).			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: TREATMENT OF PAIN			
(57) Abstract A method of treating pain by the co-administration of an antidepressant together with one or more precursors or inducers of neurotransmitters, particularly amino acids selected from L-phenylalanine, L-tyrosine, L-tryptophan and L-DOPA.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TREATMENT OF PAIN

Field of the Invention

The invention relates to the treatment of pain.

Background

Pain is one of the most important and feared symptoms of disease. Pain can be broadly divided into three classes:

1. Pain with a clearly defined cause which activates a normal nervous system and which can be effectively treated by removal of the cause, and usually alleviated by analgesics such as non-steroidal anti-inflammatories and opiates. Examples are pain due to trauma, infection or pathology such as an invading cancer.

2. Pain which appears to originate in damage to the central or peripheral nervous system itself and which may persist long after the original cause of the damage has been removed. This type of pain is usually called neuropathic or neuralgic and has many causes. Any form of trauma or other damage to any peripheral nerve or to certain parts of the central nervous system may be followed by prolonged pain which may persist for months, years or decades. The damage may be caused by accidental or surgical injury, by metabolic disturbances such as diabetes or vitamin B12 or other nutrient deficiency, by ischaemia, by radiation, by autoimmune attack, by alcohol, by infections, especially viral infections, particularly with the herpes virus, by tumours, by degenerative diseases, or by unknown factors such as may be operative in trigeminal and other neuralgias. This is by no means an exhaustive list. These types of pain often respond poorly to treatment and patients suffering them have frequently been subjected to trials of many different drugs without success. The most consistent successes are perhaps achieved with antidepressant drugs of various types. A drug for temporal lobe epilepsy, carbamazepine, is sometimes effective in trigeminal neuralgia though not usually in other types of pain in this class.

3. Pain of indeterminate origin. Many pains cannot easily be classified into one or other of these types. It is not clear whether many headaches and migraines are in type 1 or type 2. Low back pain is also often difficult to define.

Any individual who is experiencing pain immediately wants it relieved. Fortunately pain of the first type can often be treated successfully although this is not always the case. Pain of the second and third types is often poorly responsive to existing methods of treatment and many patients have tried large numbers of drugs without real success. The problems of dealing with such pain have been well described in recent articles such as those by J. W. Scadding, pp 3936 to 3946 in the 3rd edition of the Oxford Textbook of Medicine, Oxford University Press, 1996; R. G. Kost and S. E. Straus in the New England Journal of Medicine 335: 32-42, 1996; and B. S. Galer in Neurology, 45, Supplement 9, S17-S25, 1996.

Present Work

We have unexpectedly found a new approach to treating pain, especially pain of the second and third types described above, which appears to be much more effective than treatments currently available. This involves the administration of an antidepressant and a neurotransmitter precursor or inducer. The antidepressant may be one of any of the classes of antidepressant, but particularly tri- and tetra-cyclic and related compounds, selective and non-selective monoamine oxidase inhibitors, selective serotonin reuptake inhibitors and any other classes of compound which are believed to exert their antidepressant action by enhancing the effects of the catecholamine or serotonin classes of neurotransmitter substances.

We have conducted a comprehensive literature search and can find no references to the combined administration of an antidepressant and a neurotransmitter precursor or inducer for the treatment of pain. In particular we can find no reference to the co-administration of lofepramine and L-phenylalanine in pain management. There are very many papers on the uses of antidepressants in pain, as illustrated by the three papers mentioned above, but none

of these to our knowledge discuss the simultaneous coadministration of a neurotransmitter precursor or inducer.

Nevertheless we understand that another inventor, Dr. Andrew Worsley, has made a related invention and has filed for patent protection (U.K. 9614121.3 of 5th July 1996 and another application thereafter). Dr Worsley's discovery also relates to relief of pain by combinations of phenylamine and antidepressants but relates specifically to pain originating from peripheral neuropathies and especially diabetic neuropathy. Pain resulting from specific peripheral nerve damage and specifically the pain of diabetic neuropathy, are therefore excluded from this application.

The Invention

The invention is as set out in the claims herein but broadly lies in the use of an antidepressant drawn from one of the classes mentioned, together with one or more neurotransmitter precursors or inducers for the treatment of any type of pain but particularly for neuropathic pain and pain of uncertain origin, including headache, migraine and back pain. The actives may be administered together or separately but so as to be present in the body together.

The invention also extends to pharmaceutical compositions of an antidepressant and a neurotransmitter precursor or inducer when for the treatment of pain, and to methods of making pharmaceutical compositions for the treatment of pain, wherein the actives are an antidepressant and a precursor or inducer of a neurotransmitter, or one such active when the composition is for use in conjunction with administration of the other.

In addition to the two major components, such pharmaceutical preparations or compositions may also contain one or more of vitamin B12, folic acid, vitamin B6, tetrahydrobiopterin and other compounds required for normal nerve metabolism.

Specific Formulations

The antidepressant which we have found to be most effective is lofepramine but, as stated, any other antidepressant may be used. Among suitable neurotransmitter precursors are L-phenylalanine, L-tyrosine or L-DOPA of the pathway leading to the synthesis of dopamine, noradrenaline and adrenaline, or alternatively tryptophan of the pathway leading to serotonin. More than one may be administered although we have observed particularly good results with L-phenylalanine. In addition, various co-factors known to be important in the nervous system or in the biosynthesis of the neurotransmitters may also be administered. Such compounds include folic acid, vitamin B12, tetrahydrobiopterin and vitamin B6.

The preferred antidepressant in the formulations is, as stated, lofepramine, but any other antidepressant may be used, including imipramine, amitriptyline, nortriptyline, mianserin, trimipramine, clomipramine, protriptyline, fluvoxamine, pargyline, triazolopyridine, phenelzine, tranlycypromine, moclobemide, fluoxetine, maprotiline, sertraline, venlafaxine, dothiepin, doxepin, paroxetine, viloxazine and others. Likewise the preferred neurotransmitter precursor in the formulation is, as stated, L-phenylalanine but this may be replaced or supplemented by L-tyrosine, L-tryptophan or L-DOPA.

The actives may be formulated separately or together in any appropriate formulation known to those skilled in the art, using appropriate excipients if necessary. The compounds may be formulated in any appropriate way, such as tablets, capsules, powders, emulsions, other liquid formulations, parenteral formulations and topical formulations for transcutaneous, rectal or vaginal or other route of administration. The two or more compounds may be formulated separately but provided together in a single pack.

The antidepressant component of the formulation will be provided in a dose that is active in conjunction with the neurotransmitter precursor or inducer and appropriate to the specific antidepressant, and will be adjusted by the doctor in accordance with conventional principles. Lofepramine, for example, may be provided in a daily dose of from 30 to 300 mg

but usually of from 70 to 140 mg. The doses of the neurotransmitter precursors can be more flexible but will be in the range of 1 mg to 20 g per day, preferably 50 mg to 5 g per day and very preferably 300 mg to 3 g per day.

Composition Examples

The following are suitable compositions for administration against pain.

Example 1

Capsules of 70 mg lofepramine and 500 mg L-phenylalanine, bd.

Example 2

Capsules of 1 x 70 mg lofepramine, 2 x 500 mg L-phenylalanine. bd.

Example 3

Capsules as in Example 1 for administration, bd, with the normal requirement of vitamin B12 weekly by injection.

Example 4

Capsules of 50 mg amitriptyline and 250 mg L-phenylalanine, bd.

Case Histories

The following illustrate treatment according to the invention.

A 46 year old man suffered from intractable trigeminal neuralgia of many years standing. He had tried innumerable approaches to treatment including cryosurgery, nerve decompression, carbamazepine, phenytoin, diazepam, morphine, a long series of non-steroidal anti-inflammatories, fluoxetine, methylprednisolone, multivitamins and minerals, and tricyclic antidepressants. None had provided more than transient relief for a few days, which both he and his doctors attributed to placebo effects. He then was treated with lofepramine, 70 mg bd, together with L-phenylalanine, 500 mg bd. Within two days his pain was relieved and he has now been free of pain for three months.

A 49 year old woman suffered from chronic headache of unknown origin, exacerbated by migraines every two weeks or so. A very wide range of medications, including

antidepressants, had proved ineffective over a period of ten years. A combination of 50 mg bd amitriptyline plus 250 mg bd L-phenylalanine produced relief of the chronic headache within 48 hours and has prevented the development of any migraines over a period of two months.

A 34 year old man suffered chronic low back pain after a sports injury when he was 25. A variety of analgesics had produced partial relief but no long term freedom from pain. A surgical attempt at treatment had left him with pain worse than before. A combination of lofepramine 70 mg bd and 1g of L-phenylalanine produced relief within 72 hours which has persisted for over two months.

In this description and in the claims, the disclaimer in relation to pain caused by specific peripheral neuropathies is made with the intention of delineating the present filings from those Dr Worsley is understood to have made; it is thus in respect only of the countries of his patent applications.

CLAIMS

1. A method of treating pain of any type, especially pain of unknown origin but excluding pain caused by diabetic neuropathy or other specific peripheral neuropathies, by the co-administration of an antidepressant together with one or more precursors or inducers of neurotransmitters, particularly amino-acids selected from L-phenylalanine, L-tyrosine, L-tryptophan and L-DOPA.
2. As claim 1 but where the antidepressant is a tri- or tetra-cyclic antidepressant, a selective or non-selective monoamine oxidase inhibitor or a selective serotonin reuptake inhibitor
3. As claim 1 or 2 but where the antidepressant is lofepramine and the amino acid is L-phenylalanine.
4. A method of preparing a medication for treating pain of the type set out in claim 1, wherein use is made of compounds of the kinds set out in claim 1, 2 or 3, or one kind where the medication is for administration with the other.
5. Pharmaceutical compositions for the treatment of pain of the type set out in claim 1, comprising compounds of the kinds set out in claim 1, 2 or 3.
6. As claims 1-5 but with, or for co-administration with, one or more other nutrients or co-factors important in nerve function, particularly folic acid, vitamin B12, tetrahydrobiopterin and vitamin B6.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/02295

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/645 A61K31/405 A61K31/195 //(A61K31/645,31:405,
31:195)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 11009 A (LODER CARI) 18 April 1996 see the whole document ---	1-6
Y	US 4 431 670 A (HELLER BERNARDO) 14 February 1984 see the whole document ---	1-6
Y	US 4 652 559 A (SZMUSZKOVICZ JACOB) 24 March 1987 see abstract -----	1-6

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

B document member of the same patent family

Date of the actual completion of the international search

20 January 1998

Date of mailing of the international search report

30.01.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 97/02295

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1-2
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
In view of the large number of compounds which are defined by the wording of the claims, the search has been performed on the general idea and compounds mentioned in the examples of the description.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 5.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/02295

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9611009 A	18-04-96	AU 3612695 A	02-05-96
		CA 2200761 A	18-04-96
		EP 0784476 A	23-07-97
		FI 971290 A	02-06-97
		GB 2308065 A	18-06-97
		NO 971539 A	04-04-97
		PL 319830 A	01-09-97
		ZA 9508391 A	06-05-96

US 4431670 A	14-02-84	US 4355044 A	19-10-82

US 4652559 A	24-03-87	US 4540690 A	10-09-85
		AU 6350486 A	15-01-87
		AU 562051 B	28-05-87
		AU 9134382 A	18-08-83
		DK 53083 A	10-08-83
		EP 0085811 A	17-08-83
